<DOC>
	<DOCNO>NCT00850590</DOCNO>
	<brief_summary>Studies investigate single dos different NRL001 formulation show formulation-dependent difference exposure , even though similar effect mean anal resting pressure ( MARP ) . This study first step investigate hypothesis good balance desire anal effect undesired systemic effect reach NRL001-slow release suppository previously study formulation . To purpose , single dose 5 15 mg , administer 1 g 2 g suppository , investigate regard pharmacokinetics systemic effect ( blood pressure , pulse rate , electrocardiographic heart rate ) .</brief_summary>
	<brief_title>Study Escalating Doses NRL001 Given Slow-release Rectal Suppositories Different Weights</brief_title>
	<detailed_description />
	<criteria>1 . Healthy adult male female volunteer ( determined medical history , physical examination , laboratory test value , vital sign , electrocardiograms [ ECGs ] screen ) age 1845 year . 2 . Nonsmokers 3 month receive first dose duration study . 3 . Body Mass Index ( BMI ) ≥ 18 ≤ 30 kg/m2 . 4 . Able willing receive rectal treatment . 5 . Able voluntarily provide write informed consent participate study . 6 . Must understand purpose risk study agree follow restriction schedule procedure define protocol . 7 . Female volunteer must postmenopausal ( least one year confirm serum FSH screening ) , surgically sterile , practise true sexual abstinence , use two highly effective method contraception follow throughout study post study physical : contraceptive implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) , vasectomise partner barrier method ( condom occlusive cap ) spermicidal foam/gel/film/cream/suppository . 8 . Hormonal IUD method contraception must establish period 3 month prior dose change altered study . 9 . Females child bear potential must negative pregnancy test screening ( βHCG ) prior dose . 10 . Sexually active male volunteer must use condoms partner throughout study 90 day completion study addition normal mode contraception . 11 . Male volunteer must donate sperm study 90 day completion study . 12 . Must willing consent data enter The Over Volunteering Prevention System . 13 . The volunteer 's primary care physician must confirm nothing medical history would preclude enrolment clinical study . 1 . Positive HIV , hepatitis B , hepatitis C demonstrate result test screen . 2 . History presence significant cardiovascular , pulmonary , hepatic , renal , haematological , gastrointestinal ( GI ) , endocrine , immunologic , dermatologic , neurologic psychiatric disease . 3 . History presence aortic stenosis hypertrophic cardiomyopathy . 4 . History presence anorectal condition , clinically significant latex allergy clinically significant drug allergy . 5 . Presence ECG abnormality ( rest exercise stress test ) . 6 . Pregnant lactating female . 7 . Laboratory value screen &gt; 1.5x upper limit normal parameter &lt; 1.5x low limit normal parameter , applicable , abnormal deem clinically significant accord BioKinetic Europe Ltds SOPs , unless agree advance Sponsor 's Responsible Medical Officer BioKinetic Investigator . 8 . Current history drug alcohol abuse positive drug abuse test screening check . 9 . Volunteers , opinion Investigator , unsuitable participation study . 10 . Participation clinical drug study 90 day precede initial dose study . 11 . Any significant illness screen period precede entry study . 12 . Donation blood blood product within 90 day prior study drug administration , anytime study , except require protocol . 13 . Strenuous exercise study conduct one week prior dose ( exception exercise stress test ) . 14 . Consumption alcoholic beverage within 24 hour prior dose . Abstinence require study confinement . 15 . Consumption xanthinecontaining product within 24 hour dose study confinement . 16 . Use disallow concomitant medication include overthecounter item within 14 day prior study drug administration end study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>